Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.

Cancer - 15 Apr 2022

Reizine Natalie M, Danahey Keith, Truong Tien M, George David, House Larry K, Karrison Theodore G, van Wijk Xander M R, Yeo Kiang-Teck J, Ratain Mark J, O'Donnell Peter H

Abstract excerpt

BACKGROUND: In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, germline pharmacogenomic testing is not. This study hypothesizes that comprehensive germline pharmacogenomic profiling could have high relevance for cancer care. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 35090043
DOI: 10.1002/cncr.34104
PMCID: PMC9153953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.PMID 35090043Read ↗

Modern developments in germline pharmacogenomics for oncology prescribingSemantic proximity Read ↗

CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERSSemantic proximity Read ↗

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.Semantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersSemantic proximity Read ↗

Germline oncopharmacogenetics, a promising field in cancer therapy.Semantic proximity Read ↗

Genetic variation in human drug-related genesSemantic proximity Read ↗

How to Transition from Single‐Gene Pharmacogenetic Testing to Preemptive Panel‐Based Testing: A TutorialSemantic proximity Read ↗

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Semantic proximity Read ↗

Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute.Semantic proximity Read ↗

Pharmacogenomic discovery approaches: will the real genes please stand up?Semantic proximity Read ↗

Germline genetic variants with implications for disease risk and therapeutic outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.